Alphavirus replicon particles as immunological adjuvants
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 11, 2012
Grant Date -
Aug 23, 2012
app pub date -
Sep 12, 2007
filing date -
Sep 12, 2006
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully